SB969 requires most Hawaii health insurance coverage to include biomarker testing beginning with policies, contracts, and plans issued or renewed on or after January 1, 2026. The mandate applies to individual and group accident and health or sickness insurance policies, hospital and medical service plan contracts, health maintenance organization coverage, and Medicaid managed care plans, with an exception for limited benefit health insurance. The bill defines biomarker testing broadly to include tests of tissue, blood, or other biospecimens, including single-analyte tests, multiplex panels, protein expression testing, and whole exome, whole genome, and whole transcriptome sequencing.
The bill specifies that coverage must be available when supported by medical and scientific evidence, including FDA labeling, FDA-approved drug indications, FDA warnings and precautions, Medicare coverage determinations, and nationally recognized clinical practice guidelines or consensus statements. It also requires coverage to be provided in a way that minimizes disruptions in care, including avoiding multiple biopsies where possible, and it allows insurers to apply copayments, deductibles, and coinsurance only on terms no less favorable than those for other covered medical services. Insurers and mutual benefit societies must also provide a clear exception process and give written notice to policyholders, subscribers, and members by the end of 2026.
SB969 would amend Hawaii insurance law by adding new biomarker-testing coverage requirements to chapter 431 for health insurers and chapter 432 for health maintenance organizations, and it would extend the reimbursement requirement to Medicaid managed care plans subject to federal approval of state plan amendments. The bill would create new statutory coverage obligations for insurers, mutual benefit societies, HMOs, and Medicaid managed care administrators, while also requiring administrative notices and exception procedures. If enacted, it would expand access to precision medicine-related diagnostic testing and likely increase covered benefits and insurer compliance obligations starting in 2026.
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall sentiment appears supportive and policy-driven rather than contested. The measure is framed as a coverage expansion for medically necessary testing and is presented in a straightforward mandatory-coverage format, suggesting an intent to improve access to modern diagnostic tools. No opposing arguments, amendments, or recorded roll-call votes are included in the available context.
The main potential points of contention are likely to be cost, utilization management, and the scope of required coverage. Insurers may be concerned about premium impacts, administrative burden, and the breadth of the definition of biomarker testing, especially given the inclusion of advanced genomic sequencing and coverage based on clinical guidelines and consensus statements. Another possible issue is how exceptions will be handled and whether the bill sufficiently preserves insurer medical-necessity review authority while still ensuring timely access for patients and providers. Medicaid implementation also depends on federal approval, which could affect timing and administration.